TNXP
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E N/A, P/S 15.54, P/B 0.75
- P/B ratio of 0.75 suggests asset-based value
- P/S ratio of 15.54 is excessive
- No Graham Number due to lack of earnings
Ref Revenue Growth 108.8%, Forward P/E -2.78
- Triple-digit revenue growth (108.8%)
- Negative forward P/E
- Consistent earnings misses
Ref Historical Price Performance
- 5-year return of -100%
- 3-year return of -99.8%
Ref Piotroski F-Score 1/9, ROE -64.48%
- Low Debt/Equity
- High Current Ratio
- Piotroski F-Score 1/9
- Negative ROE/ROA
Ref Dividend Yield N/A
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for TNXP and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding Corp.
Primary
|
-100.0% | -99.8% | -4.1% | -27.7% | -4.4% | +10.5% |
|
ANIK
Anika Therapeutics, Inc.
Peer
|
-62.2% | -47.2% | -6.6% | +63.8% | +38.5% | +0.6% |
|
HITI
High Tide Inc.
Peer
|
-71.8% | +84.9% | +18.3% | -32.1% | -5.7% | +0.9% |
|
OGI
Organigram Global Inc.
Peer
|
-84.9% | -32.0% | +46.1% | -22.4% | +7.0% | +9.3% |
|
PRQR
ProQR Therapeutics N.V.
Peer
|
-66.2% | -8.3% | +74.6% | -28.4% | +15.7% | +7.6% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding Corp.
|
BEARISH | $203.71M | - | -64.5% | -% | $14.34 | |
|
ANIK
Anika Therapeutics, Inc.
|
BEARISH | $204.78M | - | -6.7% | -9.6% | $14.2 | Compare |
|
HITI
High Tide Inc.
|
BEARISH | $204.8M | - | -39.7% | -7.4% | $2.33 | Compare |
|
OGI
Organigram Global Inc.
|
BEARISH | $209.6M | 13.82 | 4.6% | 6.5% | $1.52 | Compare |
|
PRQR
ProQR Therapeutics N.V.
|
BEARISH | $209.67M | - | -61.2% | -258.1% | $1.99 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-31 | LEDERMAN SETH | Chief Executive Officer | Purchase | 5,000 | $63,100 |
| 2026-03-18 | LEDERMAN SETH | Chief Executive Officer | Purchase | 15,000 | $223,350 |
| 2025-12-31 | SAENGER BRADLEY | Chief Financial Officer | Stock Award | 701 | $9,407 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Past News Coverage
Recent headlines mentioning TNXP from our newsroom.